Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:08:22 EST Fri 23 Jan 2026
Enter Symbol
or Name
USA
CA



Q:AKTX - AKARI THERAPEUTICS PLC SPON ADR EACH REPR 2000 ORD - https://www.akaritx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AKTX - Q0.10.2296·0.620.30.2736+0.00521.9406.2932680.279  0.28  0.25311.7225  0.217819:45:39Jan 0915 min RT 2¢

Recent Trades - Last 10 of 268
Time ETExPriceChangeVolume
19:45:39Q0.28060.012214
18:29:55Q0.2810.012622
18:05:16Q0.2810.0126100
18:03:17Q0.248-0.0204124
18:02:53Q0.24-0.02848,470
18:02:15Q0.2622-0.006285
16:04:56Q0.27360.00521
16:00:02Q0.27360.0052868
15:59:58Q0.27370.0053100
15:59:58Q0.27320.004820

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-09 09:00U:AKTXNews ReleaseAkari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
2026-01-08 09:15U:AKTXNews ReleaseAkari Therapeutics to Present at the 2026 Biotech Showcase
2025-12-30 09:15U:AKTXNews ReleaseAkari Therapeutics Issues 2025 End of Year Letter to Shareholders
2025-12-23 08:30U:AKTXNews ReleaseAkari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
2025-12-18 08:30U:AKTXNews ReleaseAkari Therapeutics Releases Virtual Investor "What This Means" Segment
2025-12-16 09:29U:AKTXNews ReleaseAkari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
2025-12-09 08:40U:AKTXNews ReleaseAkari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
2025-12-04 09:00U:AKTXNews ReleaseAkari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
2025-11-25 09:00U:AKTXNews ReleaseAkari Therapeutics Announces Release of the Next CEO Corner Segment
2025-11-18 08:35U:AKTXNews ReleaseAkari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
2025-11-10 08:30U:AKTXNews ReleaseAkari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
2025-11-04 09:25U:AKTXNews ReleaseAkari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
2025-10-30 08:35U:AKTXNews ReleaseAkari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
2025-10-22 09:05U:AKTXNews ReleaseAkari Therapeutics Announces Launch of CEO Corner Platform
2025-10-15 08:30U:AKTXNews ReleaseAkari Therapeutics Announces $2.5 Million Registered Direct Offering
2025-10-09 08:45U:AKTXNews ReleaseAkari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
2025-10-03 09:30U:AKTXNews ReleaseAkari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
2025-09-24 08:45U:AKTXNews ReleaseAkari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
2025-09-17 08:45U:AKTXNews ReleaseAkari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
2025-09-05 06:45U:AKTXNews ReleaseAkari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference